Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 22 January at 4:30pm because of system upgrades. We expect to open them again on Friday 23 January  at 8am the latest.

To main content To sitemap To news Check availability details

Industrial-Scale Production of Human Pluripotent Stem Cells Using Novel Media and Bioreactors

Reference number
Coordinator Lancell AB
Funding from Vinnova SEK 1 000 000
Project duration November 2024 - October 2025
Status Completed
Venture Utlysning Infrastruktur for the development of accurate drug treatment
Call Use infrastructures to develop precision medicine

Important results from the project

We managed to demonstrate that the technical solution works on an industrial scale and is significantly more efficient and cost-effective than existing solutions through cultivation in a new type of bioreactor.

Expected long term effects

If this invention is commercialized, we expect that it will be cheaper and easier to research human pluripotent stem cells and that these will be able to reach the clinical phase.

Approach and implementation

Apart from some unexpected technical challenges, the project was carried out as planned.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 5 December 2025

Reference number 2024-02551